Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.In Cell Art and Open Monoclonal Technology (OMT), a Californian biotechnology company developing fully human monoclonal antibodies (mAb) using its proprietary platform, have signed a collaboration agreement for the generation of novel monoclonal antibodies using OMT transgenic rats and ICAntibodies, which is In Cell Art’s DNA immunisation technology.
Subscribe to our email newsletter
In Cell Art’s ICAntibodies is an integrated process for antigen design, nanocarriers/DNA formulation and genetic immunisation in mice, rats and rabbits.
In the absence of recombinant protein, In Cell Art’s patented formulation technologies allow for the production, starting from protein accession number – of functional antibodies against any natively expressed antigen.
In Cell Art is scaling up its production capacity in order to accelerate the discovery, screening and development of its partners’ new therapeutic or diagnostic antibodies.
Chloe Bellocq, CEO and Bruno Pitard, scientific adviser and co-founder of In-Cell Art, said: “Our proprietary technology for DNA formulation and antibody production (polyclonal and monoclonal) is meeting with great success.
“We are pleased and honoured that an increasing number of scientists are using our technology, which allows projects to start from antigenic in silico sequence, and no longer requires peptide or protein production for immunisation.
“Our partnership with OMT (Open Monoclonal Technology) aims to produce fully human antibodies, which will validate ICAntibodies technology in OMT’s proprietary humanised rats.”
Roland Buelow, CEO of OMT, said: “Our initial tests of In Cell Art’s DNA immunisation technology were encouraging, and we are pleased to take this next step and begin a collaboration [programme]. Clearly DNA immunisation will make it easier to generate monoclonals specific for proteins that are difficult to purify.”